Presidential Symposium
Invited discussant
Date
20 Dec 2015Session
Presidential SymposiumPresenters
Tony S.K. MokAuthors
T.S.K. MokAuthor affiliations
- Department Of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong/CN
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
656 - Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
Presenter: Keunchil Park
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
1374 - KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy
Presenter: Roy S. Herbst
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
856 - Prioritizing strategies to address the economic impact of cancer in Southeast Asia
Presenter: Nirmala Bhoo-Pathy
Session: Presidential Symposium
Resources:
Abstract
Invited discussant
Presenter: Roman Rouzier
Session: Presidential Symposium
Resources:
Slides
Webcast
Invited discussant
Presenter: Pasi Jänne
Session: Presidential Symposium
Resources:
Slides
Webcast